Shionogi’s Naldemedine Shines in Phase 3

Japanese drugmaker Shionogi’s opioid-induced constipation candidate naldemedine met the primary endpoint in a Phase 3 trial.

Specifically, 47.6 percent of patients experienced an increase in the frequency of spontaneous bowel movements from baseline for at least nine of 12 weeks versus 34.6 percent of patients on placebo.

Tested in patients with chronic non-cancer pain, naldemedine also improved secondary endpoints.